May 3 |
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
|
May 3 |
SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
May 2 |
SpringWorks Therapeutics GAAP EPS of -$1.18, revenue of $21M
|
May 2 |
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
|
May 1 |
SpringWorks Therapeutics Q1 2024 Earnings Preview
|
Apr 25 |
SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
|
Apr 24 |
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Apr 19 |
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
|
Apr 18 |
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
|
Mar 4 |
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
|